Kennedy Capital Management LLC Grows Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Kennedy Capital Management LLC increased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 29.8% in the 4th quarter, HoldingsChannel reports. The firm owned 752,580 shares of the medical device company’s stock after buying an additional 172,648 shares during the quarter. AtriCure makes up 0.5% of Kennedy Capital Management LLC’s portfolio, making the stock its 24th largest position. Kennedy Capital Management LLC’s holdings in AtriCure were worth $22,999,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in ATRC. Heck Capital Advisors LLC bought a new position in AtriCure in the fourth quarter worth about $60,000. Venturi Wealth Management LLC increased its holdings in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after purchasing an additional 2,100 shares during the period. KBC Group NV lifted its position in shares of AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd bought a new stake in AtriCure in the fourth quarter valued at approximately $89,000. Finally, AlphaQuest LLC boosted its holdings in AtriCure by 855.1% during the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company’s stock worth $155,000 after purchasing an additional 4,532 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on ATRC. Needham & Company LLC reiterated a “buy” rating and set a $51.00 target price on shares of AtriCure in a research report on Thursday, March 27th. Stifel Nicolaus lifted their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Piper Sandler boosted their price target on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Canaccord Genuity Group decreased their price target on AtriCure from $66.00 to $52.00 and set a “buy” rating on the stock in a report on Friday, March 28th. Finally, BTIG Research reissued a “buy” rating on shares of AtriCure in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.44.

Insider Buying and Selling

In other news, Director Karen Prange sold 6,100 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares of the company’s stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.20% of the company’s stock.

AtriCure Trading Up 8.1 %

Shares of ATRC opened at $33.10 on Thursday. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.62 billion, a P/E ratio of -34.84 and a beta of 1.65. The stock’s fifty day simple moving average is $36.34 and its 200 day simple moving average is $34.23. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.